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Learning lessons in sepsis from
the children
Steven Timmermans1,2 & Claude Libert1,2
Sepsis research has had relatively limited
therapeutic success so far. In their recent
study, Kobzik and colleagues (Joachim
et al, 2018) identify novel drug-sensitive
pathways in sepsis, derived exclusively
from patient data. Their strategy is based
on the analysis of a naturally sepsis-resis-
tant population (pre-puberty children) and
on the implementation of a novel-rich
Pathway Drug Network, constructed from
human gene expression data enriched in
drug–pathway–gene clusters.
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S epsis is a dysregulated host responseto infection that potentially leads toorgan failure, blood pressure decline,
and death. The yearly number of cases
worldwide is estimated to be at least
20 million. With a mean lethal response of
25%, targeting sepsis is clearly a major
unmet medical need.
Sepsis research is considered to be notori-
ously difficult. Over the past decades, huge
investments have been made both by
academic researchers and pharmaceutical
companies, but no obvious candidate drugs
have survived clinical trials and hit the
market. Several companies have had major
financial drawbacks due to these failed
attempts, and therefore, the fear for invest-
ment in sepsis research is substantial. One
can wonder why these immense efforts have
not led to therapeutic success so far. While
one can criticize the setup of many clinical
trials (Opal et al, 2014), a major issue is the
translation of pre-clinical animal work to the
real clinical situation. The use of animal
models such as mice is well motivated, but
the differences in response to sepsis between
mice and men may be simply too big (Seok
et al, 2013). Moreover, there are substantial
basic physiological differences between mice
and humans. For example, given the fact
that sepsis involves a significant metabolic
crisis, mice, which have a much larger
surface/volume ratio than men, go into
hypothermia, while humans do not. Also,
the husbandry of mice in animal houses
with specific pathogen-free conditions may
lead to very unnatural gut microbiota
compositions, leading to immature deviant
immune responses compared to the natural
outside world (Beura et al, 2016; Wilmore
et al, 2018).
Hence, research breakthroughs yielding
new candidate drug targets, by directly
analyzing human sepsis patient data, are
important but remain rather underexplored.
In their recent study, Kobzik and colleagues
(Joachim et al, 2018) describe such a
successful endeavor. The innovative aspect
of their work is twofold (Fig 1). First, they
focus on two patient groups that respond
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Figure 1. Resistance to sepsis in children links to candidate drugs via a rich Pathway Drug Network.
The workflow used in the study by Joachim et al (2018) involves two key aspects. First, the authors constructed
the PDN, based on the Comparative Toxicogenomics Database (CTD), the Pharmacogenomics Knowledgebase
(PharmGKB), the Connectivity Map (CMap), and Pathprint. Second, they used this PDN to compare differential
pathways between children and adults undergoing sepsis, to identify candidate drugs, which were then
validated in a mouse model.
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quite differently to clinical sepsis, namely
pre-puberty children that are known to be
significantly less sensitive to sepsis-induced
lethality compared to the second group,
post-puberty adults. The reduced response
to sepsis in pre-puberty children is a
well-known phenomenon amongst doctors
(Watson et al, 2003) and is in fact not
limited to sepsis, but applies to many infec-
tious diseases in general. Not much is
known about the underlying mechanisms
involved. The authors righteously consider
this relative resistant pre-puberty population
as a sort of “experiment of nature” that the
research community could interrogate.
Secondly, Joachim et al (2018) employed a
pathway-level approach, rather than a
common gene-level analysis, and processed
their patient transcriptomics results with a
Pathway Drug Network (PDN). This PDN
was newly constructed form drug–gene,
disease–gene, drug–disease, and pathway–
gene interaction sets, along with the expres-
sion data of more than 58,000 human publi-
cally available microarrays from the Gene
Expression Omnibus (GEO) database.
Their unique PDN method was applied
on pathways identified in microarray data
obtained from 167 adult (18–91 years old,
mean age 59) and 95 pre-puberty sepsis
patients (5–11 years old, mean age 8) (via
Pathprint). The four main pathway clusters
(up-regulated in children, down-regulated in
adults; down-regulated in children, up-regu-
lated in adults; up-regulated in children,
unchanged in adults and down-regulated in
children, unchanged in adults) were used to
extract subnetworks from their PDN that
correspond to the pathways that differ
between the two patient groups. They were
then able to obtain a ranking of potential
drug candidates. They selected the top 10
candidate drugs that were associated with
the pathways that differ between pre- and
post-puberty patient microarray profiles.
Most of these 10 compounds had never been
linked to sepsis before, and indeed, several
conferred some protection in a mouse model
of endotoxemia. Of course, it remains to be
seen whether some of these drugs will lead
to a breakthrough in sepsis management in
human patients.
The innovative aspect of this approach is
that the authors are able to predict path-
ways which are important in sepsis, as well
as drugs associated with these pathways,
exclusively based on sepsis gene expression
data of blood samples of two groups of
patients with a different disease response.
There are no animal models involved.
Although one may argue that the bulk of the
data in the PDN network are derived from
cell lines or from diseases with little or no
association with sepsis, nevertheless, the
drug to gene pathways to disease links are
extremely rich and form the basis of the
success of the study. Moreover, the applica-
tion of the PDN network to sepsis is likely
only one example of the spectrum of appli-
cations of this approach. If we consider this
approach as a proof of principle, it will be
interesting to see which other drug targets
will be identified for sepsis from follow-up
studies, using larger patient groups and
more sepsis subgroups. Indeed, one may
expect other results from (and other drugs
for), say a pneumonia compared to a menin-
gitis or a bladder sepsis patient.
Clearly, the construction of the PDN data-
base could serve as inspiration for future
approaches. For example, in modern inten-
sive care units, hundreds of measurements
are obtained from sepsis patients each day
of hospitalization (blood pressure, tempera-
ture, blood chemistry, organ function read-
outs, etc.). This collection of data, as well as
RNA-seq data, when integrated with PDN-
like networks in future analyses, could likely
enhance the approach described by Joachim
et al (2018).
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